Reviewing the Latest Research with **MDMA** and **MDE**

A conference organized by the Multidisciplinary Association for Psychedelic Studies

August 30 — September 1, 1999 • Dead Sea Hyatt - Israel

**MAPS sponsored an international conference** on the clinical use of MDMA, August 31 and September 1, 1999, attended by representatives from every team in the world that has administered MDMA to human subjects, as well as several researchers in the planning stages of such studies. The conference provided information to Israeli regulators needed in determining whether to grant permission for a pilot study of MDMA in the treatment of Post-Traumatic Stress Disorder. MAPS is seeking to sponsor this study at Ben-Gurion University of the Negev, in association with Dr. Moshe Kotler and Dr. Adam Darnell. The conference encouraged the exchange of information and collaboration between research teams around the world. Further reports about this important event will appear in future **MAPS Bulletins**. Speakers presented on the following topics:

**Therapeutic Uses**

**George Greer, MD**

Pioneering the use of MDMA in psychotherapy in the United States

**Juraj Styk, MD and Sonja Styk, MD**

Swiss Society of Physicians for Psycholytic Therapy

Review of clinical issues in MDMA-assisted psychotherapy, based on their use of MDMA with patients from 1988-1993 in Switzerland

**Deborah Mash, Ph.D.**

University of Miami, Florida.

Ibogaine research in cocaine addicts, United States, St. Kitts and Israel

*This talk is included since there are some issues common to the therapeutic use of MDMA and ibogaine.*

**Raphael Mechoulam, MD**

Hebrew University, Israel.

Clinical research with cannabinoids

*This talk is included because there are some policy and protocol design issues common to the therapeutic use of MDMA and cannabinoids.*

**Phase 1 Studies**

**Charles Grob, MD** — Harbor UCLA Medical Center.

University of California, Los Angeles.

MDMA dose-response Phase 1 safety study

**Jordi Cami, MD, Ph.D.**

Institut Muncipal d'Investigacions Mediques - Barcelona, Spain.

Phase 1 MDMA safety study
**Phase 1 Studies (cont'd)**

Franz Vollenweider, MD — University of Zürich, Switzerland.
Phase 1 MDMA Safety study in MDMA-naive subjects

Alex Gamma — University of Zürich, Switzerland.
MDMA PET Studies - Acute Effects

Reese Jones, MD — University of California, San Francisco.
MDMA Pharmacokinetics

John Henry, Ph.D. — Imperial College School of Medicine.
MDMA clinical research in England

**Drug Discrimination and Focused Safety Studies**

Efi Gouzoulis, MD — Psychiatric Department of the Technical University (RWTH) - Aachen, Germany.
Evidence from MDE research showing MDE, MDMA, etc. could belong to a new class of substances, the entactogens, and studies of memory in MDMA users v. controls

Manny Tancer, MD — Wayne State Medical School - Michigan.
MDMA drug discrimination studies

Magi Farré, MD, Ph.D. — Institut Muncipal d’Investigacions Mediques.
Study of MDMA and alcohol

Alex Gamma — University of Zürich, Switzerland.
MDMA and EEG and other measures

Wim Riedel, Ph.D. — University of Maastricht, The Netherlands.
Proposed study of MDMA and driving, cognitive and psychomotor performance

Twenty-five speakers presented at a recent conference held in Israel and sponsored by MAPS.

This event encouraged collaboration between research teams around the world.

**Neurotoxicity**

Franz Vollenweider, MD — University of Zürich, Switzerland.
MDMA PET scan study results

Pacale Gucker, Ph.D — University of Zürich, Switzerland.
MDMA PET scan study results

Matt Baggott — University of California, San Francisco.
Review of MDMA neurotoxicity literature

Jon Cole, Ph.D. — University of Liverpool, United Kingdom.
Review of research with MDMA users in England

Preclinical neurotoxicity research

**Proposed Therapy Protocols and Policy Issues**

Charles Grob, MD — Harbor UCLA Medical Center.
Proposed study of MDMA in the treatment of anxiety and depression in cancer patients

Jose Carlos Bouso, Ph.D. candidate
Universidad Autónoma de Madrid, Spain.
Proposed MDMA/Post Traumatic Stress Disorder study

Moshe Kotler, MD and Adam Darmell, MD
Ben-Gurion University of the Negev, Israel.
Proposed MDMA/Post Traumatic Stress Disorder study

Mark Kleiman, Ph.D. — UCLA School of Public Policy
Policy issues in clinical research with MDMA, risk/benefit analysis